CClinicalTrials.gg
Sign In
CompletedNCT00537875Updated Oct 8, 2015

Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens

An interventional study of Ginger and Placebo in Nausea and Vomiting, sponsored by National Research Institute of Tuberculosis and Lung Disease, Iran. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-08.

Sponsored by National Research Institute of Tuberculosis and Lung Disease, Iran · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether powdered ginger root (encapsulated ginger) is effective for reducing the frequency, duration and severity of both acute and delayed nausea and vomiting.

02

Conditions studied

  • Nausea
  • Vomiting

Browse trials for

03

In context

Nausea

822 studies on the registry are indexed under Nausea; 104 are open to participants now.

This study's enrollment of 36 is below the median of 115 across 703 interventional studies indexed under Nausea.

Browse Nausea studies →

Lead sponsor

National Research Institute of Tuberculosis and Lung Disease, Iran is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Must be able to give written informed consent.
  • Have a diagnosis of cancer and currently receiving chemotherapy containing cisplatin (any dose).
  • Scheduled to receive antiemetics: granisetron (kytril), hydrocortisone.
  • Must be able to complete study questionnaires.
  • Must be able to swallow capsules.

Exclusion criteria

Exclusion Criteria:

  • Have no clinical evidence of current or impending bowel obstruction.
  • Concurrent radiotherapy that is classified as high or intermediate risk of causing emesis.
  • Pregnant or lactating.
  • Patients taking therapeutic doses of coumadin (individuals on low-dose to maintain peripheral or central venous catheters are allowed), aspirin (individuals taking low-dose 80mg aspirin are allowed), or heparin.
  • Patients with a history of a bleeding disorder(s) in past 6 months and those experiencing thrombocytopenia.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    1

    Dietary Supplement: Ginger

  • Placebo comparator
    2

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementGinger

    Capsule, 1000 mg, BID, 3 days

  • Dietary supplementPlacebo

    Capsule, 1000 mg, BID, 3 days

06

What researchers measure

Primary outcomes

  1. Nausea, Vomiting

    Time frame: 3 days

07

Study locations

1 site
  • National Research Institute of Tuberculosis and Lung Disease (NRITLD)
    Tehran, P.O: 19575/154, Iran, Islamic Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00537875
Lead sponsor
National Research Institute of Tuberculosis and Lung Disease, Iran
Responsible party
Shadi Baniasadi (associate professor, National Research Institute of Tuberculosis and Lung Disease, Iran) — Principal investigator
First posted
Oct 2, 2007
Start date
Sep 2007
Primary completion
Sep 2008
Completion
Sep 2009
Last update
Oct 8, 2015

Study contacts

Shadi Baniasadi, Ph.D.
principal investigator · National Research Institute of Tuberculosis and Lung Disease (NRITLD)-Shaheed Beheshti University of Medical Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Nausea→

Other studies from this sponsor

National Research Institute of Tuberculosis and Lung Disease, Iran

Start the discussion